4.5 Article

Disseminated glioneuronal tumors occurring in childhood: treatment outcomes and BRAF alterations including V600E mutation

Journal

JOURNAL OF NEURO-ONCOLOGY
Volume 128, Issue 2, Pages 293-302

Publisher

SPRINGER
DOI: 10.1007/s11060-016-2109-x

Keywords

Pediatric glioma; Oligodendroglioma; Glioneuronal; Leptomeningeal neoplasms; Protooncogene proteins B-raf

Funding

  1. A Kids' Brain Tumor Cure Foundation Pediatric Low-Grade Astrocytoma Foundation
  2. Stop and Shop Pediatric Brain Tumor Program
  3. St Baldrick's Foundation
  4. Team Jack Foundation
  5. Andrysiak Fund for LGG
  6. Jared Branfman Sunflowers For Life Fund For Pediatric Brain And Spinal Cancer Research
  7. Sontag Foundation
  8. Nuovo-Soldati Foundation
  9. Philippe Foundation
  10. Pediatric Brain Tumor Foundation
  11. Royal Children's Hospital Foundation
  12. Robert Connor Dawes Foundation
  13. Murray Jackson Clinical Fellowship, Genesis Oncology Trust, New Zealand

Ask authors/readers for more resources

Disseminated glioneuronal tumors of childhood are rare. We present a retrospective IRB-approved review of the clinical course and frequency of BRAF mutations in disseminated glioneuronal tumors at two institutions. Defining features of our cohort include diffuse leptomeningeal-spread, often with a discrete spinal cord nodule and oligodendroglioma-like histologic features. Patients were identified through a pathology database search of all cases with disseminated low-grade neoplasms with an oligodendroglioma-like component. De-identified clinical information was collected by chart review and all imaging was reviewed. We retrieved the results of targeted genomic analyses for alterations in BRAF. Ten patients (aged 2-14 years) were identified from the Dana-Farber/Boston Children's Hospital and the Royal Children's Hospital, Melbourne pathology databases. Nine patients received chemotherapy. Eight patients are alive, although three have had episodes of progressive disease. We identified genomic alterations affecting the MAPK pathway in six patients. One patient had a germline RAF1 mutation and a clinical diagnosis of cardio-facio-cutaneous syndrome. BRAF duplications were identified in four and BRAF V600E mutation was identified in one. These data support the presence of targetable genomic alterations in this disease.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available